GILDKite, A Gilead CompanyRunning, no new patients
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 300 (planned)
- Started
- Feb 10, 2023
- Main results expected
- Mar 2031
- Fully finished
- Mar 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free Survival (EFS) by Blinded Central Assessment
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05605899 · record last updated 2026-04-15 · checked 2026-11-09 15:47 UTC